Johnson & Johnson wins European Commission approval for TECVAYLI combo in multiple myeloma

Johnson & Johnson said the European Commission has granted approval for TECVAYLI (teclistamab) in combination with daratumumab for adults with relapsed or refractory multiple myeloma. The decision covers use of the combination for patients whose disease has returned or does not respond to prior therapy.

The approval relates to the TECVAYLI-daratumumab regimen, which pairs teclistamab, a T-cell redirecting therapy, with daratumumab, a widely used anti-myeloma monoclonal antibody. In plain terms, the combination aims to broaden the way the immune system and targeted antibody therapy work together against cancer cells in the bone marrow.

The company’s announcement, carried by Yahoo Finance, indicates that the regulatory green light is for the combination itself, not for teclistamab alone. For manufacturers of oncology drugs, that distinction matters because pricing, prescribing patterns, and competitive positioning can differ between a monotherapy label and a multi-drug regimen.

Multiple myeloma is a chronic blood cancer with a long-term treatment cycle, and regimens are commonly sequenced as the disease relapses. Approvals in the relapsed or refractory setting can influence how physicians build treatment plans, especially when new options show benefit for patients who have already received other therapies.

Johnson & Johnson competes in multiple myeloma with a portfolio that includes daratumumab-based treatments and other immune-targeting approaches. A new combination label in Europe can strengthen the company’s position as clinicians weigh whether to switch mechanisms or intensify treatment after earlier lines of therapy.

The European Commission decision also adds another data point to the broader push among drugmakers to expand labels for established targets. Daratumumab is already a key backbone in myeloma care, and pairing it with an immune redirecting agent like teclistamab reflects an ongoing strategy to create deeper responses by using two different approaches at once.

Still, the Yahoo Finance report does not disclose in the text provided here details such as the specific trial(s) used for European approval, the size of the studied population, or the quantified efficacy and safety outcomes. Those figures are typically published separately in regulatory assessment documents or in the company’s clinical documentation, and they were not included in the material reviewed for this story.

What to watch next is whether Johnson & Johnson provides additional detail on the label scope, including any constraints by prior therapy history or dosing schedule, and how quickly the company turns the approval into uptake across European markets. For the sector, further combination approvals could pressure rivals to refine their own regimens and highlight where incremental benefits are most meaningful for relapsed or refractory patients.